Demographic data of 46 patients treated with R-LEN
| Characteristics . | No. of patients . |
|---|---|
| Total patients | 46 |
| Female | 28 (61%) |
| Male | 18 (39%) |
| Median age, y (range) | 64 (32-84) |
| Primary localization of MALT lymphoma | |
| Stomach | 14 (30%) |
| Ocular adnexa | 13 (28%) |
| Lung | 5 (11%) |
| Parotid gland | 3 (7%) |
| Other | 6 (13%) |
| Multiple extranodal sites | 5 (11%) |
| Current site of lymphoma/site of relapse | |
| Stomach | 10 (22%) |
| Ocular adnexa | 12 (26%) |
| Lung | 4 (9%) |
| Other | 8 (17%) |
| Multiple extranodal sites | 12 (26%) |
| Stage according to Ann Arbor | |
| I/IIE “localized disease” | 28 (61%) |
| III/IVE “disseminated disease” | 18 (39%) |
| ECOG performance status | |
| ECOG 0-1 | 45 (98%) |
| ECOG 2 | 1 (2%) |
| LDH elevation at baseline | 6 (13%) |
| IPI Score | |
| 0-2 | 37 (80%) |
| >2 | 9 (20%) |
| Prior treatment | |
| Systemic (immuno-/chemotherapy) | 11 (24%) |
| R-containing regimens | 9 (20%) |
| Prior lenalidomide treatment | 1 (2%) |
| >2 prior treatment lines | 9 (20%) |
| Median follow-up time in months (range) | 27.0 (13.2-36.3) |
| Characteristics . | No. of patients . |
|---|---|
| Total patients | 46 |
| Female | 28 (61%) |
| Male | 18 (39%) |
| Median age, y (range) | 64 (32-84) |
| Primary localization of MALT lymphoma | |
| Stomach | 14 (30%) |
| Ocular adnexa | 13 (28%) |
| Lung | 5 (11%) |
| Parotid gland | 3 (7%) |
| Other | 6 (13%) |
| Multiple extranodal sites | 5 (11%) |
| Current site of lymphoma/site of relapse | |
| Stomach | 10 (22%) |
| Ocular adnexa | 12 (26%) |
| Lung | 4 (9%) |
| Other | 8 (17%) |
| Multiple extranodal sites | 12 (26%) |
| Stage according to Ann Arbor | |
| I/IIE “localized disease” | 28 (61%) |
| III/IVE “disseminated disease” | 18 (39%) |
| ECOG performance status | |
| ECOG 0-1 | 45 (98%) |
| ECOG 2 | 1 (2%) |
| LDH elevation at baseline | 6 (13%) |
| IPI Score | |
| 0-2 | 37 (80%) |
| >2 | 9 (20%) |
| Prior treatment | |
| Systemic (immuno-/chemotherapy) | 11 (24%) |
| R-containing regimens | 9 (20%) |
| Prior lenalidomide treatment | 1 (2%) |
| >2 prior treatment lines | 9 (20%) |
| Median follow-up time in months (range) | 27.0 (13.2-36.3) |
IPI, International Prognostic Index.